{"id":"cyclosporine-vs-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (cyclosporine)"},{"rate":null,"effect":"Hypertension (cyclosporine)"},{"rate":null,"effect":"Infections (both agents)"},{"rate":null,"effect":"Infusion reactions (infliximab)"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine suppresses T-cell activation by inhibiting calcineurin and blocking IL-2 production, while infliximab is a chimeric monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine. Both agents reduce intestinal inflammation but through distinct immunological mechanisms.","oneSentence":"This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:31.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Severe steroid-refractory IBD"}]},"trialDetails":[{"nctId":"NCT00542152","phase":"PHASE4","title":"Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2007-06","conditions":"Ulcerative Colitis, Steroid Refractory","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclosporine (IV)= Brand Name = Sandinuum","Cyclosporine (PO)= brand name = Neoral","Infliximab (IV)= brand name= Remicade"],"phase":"marketed","status":"active","brandName":"CYCLOSPORINE VS INFLIXIMAB","genericName":"CYCLOSPORINE VS INFLIXIMAB","companyName":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","companyId":"groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease. Used for Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Severe steroid-refractory IBD.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}